YU23102A - Jedinjenja za lečenje ishemije - Google Patents
Jedinjenja za lečenje ishemijeInfo
- Publication number
- YU23102A YU23102A YU23102A YUP23102A YU23102A YU 23102 A YU23102 A YU 23102A YU 23102 A YU23102 A YU 23102A YU P23102 A YUP23102 A YU P23102A YU 23102 A YU23102 A YU 23102A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- ischemia
- agonists
- compounds
- treatment
- tissue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A3, agonisti, metode za upotrebu ovih A3 agonista i farmaceutski sastav koji sadrži ove A3 agoniste. A3 agonisti koji su korisni za redukciju oštećenja tkiva nastalog od ishemijskog ili hipoksičnog tkiva.[A3 agonists, methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15682899P | 1999-09-30 | 1999-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU23102A true YU23102A (sh) | 2006-01-16 |
Family
ID=22561263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU23102A YU23102A (sh) | 1999-09-30 | 2000-09-22 | Jedinjenja za lečenje ishemije |
Country Status (41)
| Country | Link |
|---|---|
| EP (1) | EP1216257B1 (sh) |
| JP (1) | JP2003510331A (sh) |
| KR (1) | KR100481605B1 (sh) |
| CN (1) | CN1374967A (sh) |
| AP (1) | AP2002002458A0 (sh) |
| AR (1) | AR029887A1 (sh) |
| AT (1) | ATE312117T1 (sh) |
| AU (1) | AU778185B2 (sh) |
| BG (1) | BG106636A (sh) |
| BR (1) | BR0014384A (sh) |
| CA (1) | CA2386079A1 (sh) |
| CO (1) | CO5180581A1 (sh) |
| CR (1) | CR6592A (sh) |
| CZ (1) | CZ20021020A3 (sh) |
| DE (1) | DE60024649D1 (sh) |
| EA (1) | EA005422B1 (sh) |
| EC (1) | ECSP003682A (sh) |
| EE (1) | EE200200172A (sh) |
| GE (1) | GEP20043241B (sh) |
| GT (1) | GT200000161A (sh) |
| HK (1) | HK1049011A1 (sh) |
| HR (1) | HRP20020253A2 (sh) |
| HU (1) | HUP0202807A3 (sh) |
| IL (1) | IL148222A0 (sh) |
| IS (1) | IS6286A (sh) |
| MA (1) | MA26822A1 (sh) |
| MX (1) | MXPA02003308A (sh) |
| MY (1) | MY133996A (sh) |
| NO (1) | NO20021474L (sh) |
| NZ (1) | NZ517177A (sh) |
| OA (1) | OA12021A (sh) |
| PA (1) | PA8503301A1 (sh) |
| PE (1) | PE20010696A1 (sh) |
| PL (1) | PL357371A1 (sh) |
| SK (1) | SK4182002A3 (sh) |
| TN (1) | TNSN00191A1 (sh) |
| TR (1) | TR200200843T2 (sh) |
| UA (1) | UA73525C2 (sh) |
| WO (1) | WO2001023399A1 (sh) |
| YU (1) | YU23102A (sh) |
| ZA (1) | ZA200202461B (sh) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6803457B1 (en) | 1999-09-30 | 2004-10-12 | Pfizer, Inc. | Compounds for the treatment of ischemia |
| EP1241176A1 (en) * | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| WO2003039528A1 (en) * | 2001-11-02 | 2003-05-15 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| WO2003088978A1 (en) | 2002-04-18 | 2003-10-30 | Cv Therapeutics, Inc. | Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| KR20060123292A (ko) * | 2003-11-10 | 2006-12-01 | 쉐링 악티엔게젤샤프트 | Ｃｃｒ-5 길항제로서 유용한 벤질에테르 아민 화합물 |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| WO2005092068A2 (en) | 2004-03-24 | 2005-10-06 | Fasgen, Llc | Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase |
| JP5014983B2 (ja) | 2004-05-07 | 2012-08-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | １１−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのピロリジン−２−オン及びピペリジン−２−オン誘導体 |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| DK1778239T3 (da) * | 2004-07-28 | 2013-12-02 | Can Fite Biopharma Ltd | Adenosin-a3-receptor-agonister til behandling af sygdomme forbundet medtørre øjne, herunder sjögrens syndrom |
| CA2576255A1 (en) * | 2004-08-09 | 2006-02-16 | Universite Catholique De Louvain | Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases |
| JP5137574B2 (ja) | 2004-08-30 | 2013-02-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | １１−ベータヒドロキシステロイドヒドロゲナーゼ阻害剤としての三環式ラクタム誘導体 |
| DE602005017159D1 (de) | 2004-08-30 | 2009-11-26 | Janssen Pharmaceutica Nv | Oxysteroid-dehydrogenase-inhibitoren |
| JP5208505B2 (ja) * | 2004-08-30 | 2013-06-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | １１−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのｎ−２アダマンタニル−２−フェノキシ−アセトアミド誘導体 |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| KR20080049113A (ko) | 2005-10-21 | 2008-06-03 | 노파르티스 아게 | Ｉｌ-13에 대항한 인간 항체 및 치료적 용도 |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
| EP2089393A1 (en) | 2006-10-30 | 2009-08-19 | Novartis AG | Heterocyclic compounds as antiinflammatory agents |
| JP5584138B2 (ja) | 2008-01-11 | 2014-09-03 | ノバルティス アーゲー | キナーゼ阻害剤としてのピリミジン類 |
| JP2012516345A (ja) | 2009-01-29 | 2012-07-19 | ノバルティス アーゲー | 星細胞腫治療用置換ベンゾイミダゾール |
| WO2011010306A1 (en) | 2009-07-21 | 2011-01-27 | Ramot At Tel-Aviv University Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| AU2010283806A1 (en) | 2009-08-12 | 2012-03-01 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| ES2709108T3 (es) | 2009-08-17 | 2019-04-15 | Intellikine Llc | Compuestos heterocíclicos y usos de los mismos |
| AU2010284972A1 (en) | 2009-08-20 | 2012-03-08 | Novartis Ag | Heterocyclic oxime compounds |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
| WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
| BR112014006223A8 (pt) | 2011-09-15 | 2018-01-09 | Novartis Ag | 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação |
| JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン， エルエルシー | Ｍｔｏｒ阻害剤を使用する強化された治療レジメン |
| CN104245701A (zh) | 2012-04-03 | 2014-12-24 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
| MX363473B (es) | 2012-05-08 | 2019-03-25 | Aeromics Inc | Uso de fenilbenzamidas para tratar condiciones mediadas por acuaporina. |
| RU2559776C2 (ru) * | 2012-08-20 | 2015-08-10 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| US20160279155A1 (en) | 2013-11-06 | 2016-09-29 | Aeromics, Inc. | Novel formulations |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| RU2611339C2 (ru) * | 2014-02-17 | 2017-02-21 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| MX2017001461A (es) | 2014-07-31 | 2017-05-11 | Novartis Ag | Terapia de combinacion. |
| RU2582961C1 (ru) * | 2015-03-04 | 2016-04-27 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления |
| RU2712150C1 (ru) * | 2019-08-22 | 2020-01-24 | Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" | ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK62692D0 (sh) * | 1992-05-14 | 1992-05-14 | Novo Nordisk As | |
| TW336938B (en) * | 1992-05-21 | 1998-07-21 | Pfizer | Calcium channel blocking polypeptides from filistata hibernalis |
| ATE206432T1 (de) * | 1993-07-13 | 2001-10-15 | Nasa | A3 -adenosin -rezeptor agonisten |
-
2000
- 2000-09-05 CO CO00066880A patent/CO5180581A1/es not_active Application Discontinuation
- 2000-09-22 EA EA200200316A patent/EA005422B1/ru not_active IP Right Cessation
- 2000-09-22 NZ NZ517177A patent/NZ517177A/en unknown
- 2000-09-22 YU YU23102A patent/YU23102A/sh unknown
- 2000-09-22 MX MXPA02003308A patent/MXPA02003308A/es unknown
- 2000-09-22 TR TR2002/00843T patent/TR200200843T2/xx unknown
- 2000-09-22 GE GEAP20006392A patent/GEP20043241B/en unknown
- 2000-09-22 EE EEP200200172A patent/EE200200172A/xx unknown
- 2000-09-22 HU HU0202807A patent/HUP0202807A3/hu unknown
- 2000-09-22 SK SK418-2002A patent/SK4182002A3/sk unknown
- 2000-09-22 CA CA002386079A patent/CA2386079A1/en not_active Abandoned
- 2000-09-22 AP APAP/P/2002/002458A patent/AP2002002458A0/en unknown
- 2000-09-22 DE DE60024649T patent/DE60024649D1/de not_active Expired - Lifetime
- 2000-09-22 BR BR0014384-7A patent/BR0014384A/pt not_active IP Right Cessation
- 2000-09-22 AT AT00958949T patent/ATE312117T1/de not_active IP Right Cessation
- 2000-09-22 OA OA1200200072A patent/OA12021A/en unknown
- 2000-09-22 EP EP00958949A patent/EP1216257B1/en not_active Expired - Lifetime
- 2000-09-22 CN CN00813154A patent/CN1374967A/zh active Pending
- 2000-09-22 JP JP2001526549A patent/JP2003510331A/ja active Pending
- 2000-09-22 AU AU70352/00A patent/AU778185B2/en not_active Ceased
- 2000-09-22 PL PL00357371A patent/PL357371A1/xx not_active Application Discontinuation
- 2000-09-22 CZ CZ20021020A patent/CZ20021020A3/cs unknown
- 2000-09-22 UA UA2002032515A patent/UA73525C2/uk unknown
- 2000-09-22 WO PCT/IB2000/001353 patent/WO2001023399A1/en active IP Right Grant
- 2000-09-22 KR KR10-2002-7004177A patent/KR100481605B1/ko not_active IP Right Cessation
- 2000-09-25 PA PA20008503301A patent/PA8503301A1/es unknown
- 2000-09-27 PE PE2000001021A patent/PE20010696A1/es not_active Application Discontinuation
- 2000-09-28 EC EC2000003682A patent/ECSP003682A/es unknown
- 2000-09-28 MY MYPI20004553 patent/MY133996A/en unknown
- 2000-09-28 AR ARP000105125A patent/AR029887A1/es unknown
- 2000-09-28 GT GT200000161A patent/GT200000161A/es unknown
- 2000-09-29 TN TNTNSN00191A patent/TNSN00191A1/fr unknown
- 2000-09-29 IL IL14822200A patent/IL148222A0/xx unknown
-
2002
- 2002-02-18 CR CR6592A patent/CR6592A/es not_active Application Discontinuation
- 2002-02-26 IS IS6286A patent/IS6286A/is unknown
- 2002-03-15 MA MA26557A patent/MA26822A1/fr unknown
- 2002-03-25 NO NO20021474A patent/NO20021474L/no unknown
- 2002-03-26 HR HR20020253A patent/HRP20020253A2/xx not_active Application Discontinuation
- 2002-03-27 ZA ZA200202461A patent/ZA200202461B/xx unknown
- 2002-04-23 BG BG106636A patent/BG106636A/bg unknown
-
2003
- 2003-02-18 HK HK03101216.3A patent/HK1049011A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY133996A (en) | Compounds for the treatment of ischemia | |
| AP9901478A0 (en) | Compounds for the treatment of ischemia. | |
| DE69726577D1 (en) | Kristallin form i von clarithromycin | |
| DE60112609D1 (en) | Pyrazolopyridine | |
| HUP0103567A3 (en) | 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists, process for their preparation and pharmaceutical compositions containing the same | |
| IL139862A0 (en) | Thiazolidine or pyrrolidine derivatives as dipeptidyl peptidase iv effectors and pharmaceutical compositions containing the same | |
| PL367682A1 (en) | Dolastatin 10 derivatives | |
| YU38801A (sh) | Azabicikloalkani kao modulatori ccr5 | |
| CA2292359A1 (en) | Novel azalides and methods of making same | |
| AR024138A1 (es) | Inhibidores de la proliferacion celular | |
| HK1050535A1 (en) | Novel oligosaccharides, preparation method and pharmaceutical compositions containing same | |
| DE60112330D1 (en) | Pyrazolopyridinderivate | |
| CA2378428A1 (en) | Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes | |
| YU13301A (sh) | Muskarinski agonisti i antagonisti | |
| AU6469401A (en) | Pharmaceutically active compounds and methods of use | |
| GB9907571D0 (en) | Compounds | |
| AU1878201A (en) | Composition for the treatment of damaged tissue | |
| AU2002357740A1 (en) | Pyrazolo-pyridine derivatives as antiherpes agents | |
| DE60011677D1 (en) | Tryptase-inhibitoren | |
| SI1244614T1 (en) | Tryptase inhibitors | |
| AU4944899A (en) | New pharmaceutically active compounds | |
| HK1050203A1 (en) | Novel fusidic acid derivatives. | |
| AU4920200A (en) | Compositions for the preserving treatment of feeds | |
| NZ505085A (en) | Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi | |
| TWI231815B (en) | Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents |